• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?

作者信息

Gianni Caterina, Nicolò Eleonora, Cristofanilli Massimo

机构信息

Department of Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

出版信息

Transl Breast Cancer Res. 2024 Oct 25;5:34. doi: 10.21037/tbcr-24-41. eCollection 2024.

DOI:10.21037/tbcr-24-41
PMID:39534583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11557154/
Abstract
摘要

相似文献

1
Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?激素受体阳性早期乳腺癌的辅助性CDK4/6抑制剂：一刀切可行吗？
Transl Breast Cancer Res. 2024 Oct 25;5:34. doi: 10.21037/tbcr-24-41. eCollection 2024.
2
Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors.符合辅助性CDK4/6抑制剂治疗条件的乳腺癌患者的真实世界分析。
Clin Breast Cancer. 2025 Feb;25(2):e159-e169.e2. doi: 10.1016/j.clbc.2024.08.022. Epub 2024 Aug 29.
3
Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer.临床医生指南：早期乳腺癌患者使用CDK4/6抑制剂的专家见解
Ther Adv Med Oncol. 2025 Mar 20;17:17588359251326710. doi: 10.1177/17588359251326710. eCollection 2025.
4
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy endocrine therapy alone in patients with HR+/HER2- early breast cancer.NATALEE研究的原理与试验设计：一项针对HR+/HER2-早期乳腺癌患者的辅助性瑞博西尼联合内分泌治疗与单纯内分泌治疗的III期试验。
Ther Adv Med Oncol. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125. eCollection 2023.
5
Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting.将 CDK4/6 抑制剂的临床应用从转移性疾病治疗扩展至激素受体阳性、HER2 阴性乳腺癌的辅助治疗。
Drug Des Devel Ther. 2022 Mar 16;16:727-735. doi: 10.2147/DDDT.S356757. eCollection 2022.
6
CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.CDK4/6 抑制剂作为激素受体阳性、HER2 阴性早期乳腺癌的辅助治疗：系统评价和荟萃分析。
ESMO Open. 2021 Apr;6(2):100091. doi: 10.1016/j.esmoop.2021.100091. Epub 2021 Mar 18.
7
Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.辅助性阿贝西利和瑞博西尼在高危激素受体阳性早期乳腺癌中的成本效益：印度视角
JCO Glob Oncol. 2024 Jul;10:e2300433. doi: 10.1200/GO.23.00433.
8
Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.CDK4/6抑制剂联合内分泌治疗晚期激素受体阳性（HR+）和人表皮生长因子受体2阴性（HER2-）乳腺癌的药物经济学评价：一项系统综述
Ann Transl Med. 2022 Feb;10(4):233. doi: 10.21037/atm-21-5110.
9
Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials.辅助 CDK4/6 抑制剂联合激素治疗 HR 阳性、HER2 阴性早期乳腺癌的随机临床试验的荟萃分析。
Breast. 2021 Oct;59:165-175. doi: 10.1016/j.breast.2021.07.002. Epub 2021 Jul 6.
10
[Consensus on the clinical use of CDK4/6 inhibitors for the treatment of hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer (2023 edition)].CDK4/6抑制剂治疗激素受体阳性、人表皮生长因子受体2阴性乳腺癌的临床应用共识（2023年版）
Zhonghua Zhong Liu Za Zhi. 2023 Dec 23;45(12):1003-1017. doi: 10.3760/cma.j.cn112152-20230428-00188.

引用本文的文献

1
Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies.癌症中的表观遗传失调：机制、诊断生物标志物及治疗策略
Med Oncol. 2025 Jul 21;42(8):359. doi: 10.1007/s12032-025-02905-z.
2
How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?化疗后，如何为高危激素受体阳性、人表皮生长因子受体2阴性乳腺癌选择最佳辅助治疗方法？
Acta Oncol. 2025 Jun 25;64:815-829. doi: 10.2340/1651-226X.2025.43645.

本文引用的文献

1
Ribociclib plus Endocrine Therapy in Early Breast Cancer.来曲唑联合内分泌治疗早期乳腺癌。
N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488.
2
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.辅助阿贝西利联合内分泌治疗激素受体阳性、人表皮生长因子受体 2 阴性、高危早期乳腺癌： monarchE 总生存期中期分析的预先计划结果，包括 5 年疗效结果。
J Clin Oncol. 2024 Mar 20;42(9):987-993. doi: 10.1200/JCO.23.01994. Epub 2024 Jan 9.
3
The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment.
CDK4/6 抑制剂革命——乳腺癌治疗的变革时代。
Nat Rev Clin Oncol. 2024 Feb;21(2):89-105. doi: 10.1038/s41571-023-00840-4. Epub 2023 Dec 11.
4
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer.填补CDK4/6抑制剂后的空白：转移性激素受体阳性乳腺癌的新型内分泌和生物治疗选择
Cancers (Basel). 2023 Mar 28;15(7):2015. doi: 10.3390/cancers15072015.
5
How I treat endocrine-dependent metastatic breast cancer.我是如何治疗激素依赖性转移性乳腺癌的。
ESMO Open. 2023 Apr;8(2):100882. doi: 10.1016/j.esmoop.2023.100882. Epub 2023 Feb 17.
6
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.阿贝西利联合内分泌治疗激素受体阳性、HER2 阴性、淋巴结阳性、高危早期乳腺癌（monarchE）：一项随机、开放标签、III 期临床试验的预先计划的中期分析结果。
Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6.
7
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review.高危早期激素受体阳性、人表皮生长因子受体2阴性乳腺癌的定义：一项共识性综述
Cancers (Basel). 2022 Apr 9;14(8):1898. doi: 10.3390/cancers14081898.
8
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).帕博西利辅助治疗早期乳腺癌：PALLAS 试验结果（ABCSG-42/AFT-05/BIG-14-03）。
J Clin Oncol. 2022 Jan 20;40(3):282-293. doi: 10.1200/JCO.21.02554. Epub 2021 Dec 7.
9
Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities.晚期激素受体阳性、人表皮生长因子受体2阴性乳腺癌对细胞周期蛋白依赖性激酶4/6抑制剂耐药的机制及新出现的治疗机会
Clin Cancer Res. 2022 Mar 1;28(5):821-830. doi: 10.1158/1078-0432.CCR-21-2947.
10
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.MONALEESA-2、-3 和 -7 随机试验中激素受体阳性、HER2 阴性晚期乳腺癌的剂量减少的安全性和疗效影响。
Br J Cancer. 2021 Aug;125(5):679-686. doi: 10.1038/s41416-021-01415-9. Epub 2021 Jun 22.